C-reactive protein, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, C-reactive protein

Aasheim ET, Hofso D, Hjelmesaeth J, Birkeland KI, Bohmer T 2008 Vitamin status in morbidly obese patients: a cross-sectional study. Am. J. Clin. Nutr. 87: 362-369. *
Abou-Raya A, Abou-Raya S 2006 Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun. Rev. 5: 331-337.
Abou-Raya S, Abou-Raya A, Naim A, Abuelkheir H 2007 Chronic inflammatory autoimmune disorders and atherosclerosis. Ann. N. Y. Acad. Sci. 1107: 56-67. *
Aceituno M, Garcia-Planella E, Heredia C, Zabana Y, Feu F, Domenech E, Gassull MA, Panes J 2008 Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm. Bowel Dis. 14: 347-352.
Agirbasli M, Inanc N, Baykan OA, Direskeneli H 2006 The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin. Exp. Rheumatol. 24: 580-583.
Agnholt J, Kelsen J, Brandsborg B, Jakobsen NO, Dahlerup JF 2004 Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease - a possible target for infliximab treatment. Eur. J. Gastroenterol. Hepatol. 16: 649-655.
Akman SA, Arikan C, Sozen G, Ozturk C, Yagci RV 2006 Infliximab treatment of pediatric refractory Crohn's disease: a case report. Turk. J. Gastroenterol. 17: 133-136. *
Aksungar FB, Topkaya AE, Yildiz Z, Sahin S, Turk U 2008 Coagulation status and biochemical and inflammatory markers in multiple sclerosis. J. Clin. Neurosci. 15: 393-397.
Al-Bahrani AZ, Ammori BJ 2005 Clinical laboratory assessment of acute pancreatitis. Clin. Chim. Acta 362: 26-48. *
Al-Daghri NM, Al-Attas OS, Al-Rubeaan K, Sallam R 2008 Adipocytokine profile of type 2 diabetics in metabolic syndrome as defined by various criteria. Diabetes Metab. Res. Rev. 24: 52-58.
Albert MA 2007 Inflammatory biomarkers, race/ethnicity and cardiovascular disease. Nutr. Rev. 65: S234-S238.
Aleksandra Nielsen A, Nederby Nielsen J, Schmedes A, Brandslund I, Hey H 2005 Saliva interleukin-6 in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 40: 1444-1448. *
Amano K, Amano K 1998 Filter leukapheresis for patients with ulcerative colitis: clinical results and the possible mechanism. Ther. Apher. 2: 97-100.
Ammon HP 2006 Boswellic acids in chronic inflammatory diseases. Planta Med. 72: 1100-1116.
An Y, Xiao YB 2007 Growth hormone prevents acute liver injury induced by cardiopulmonary bypass in a rat model. J. Thorac. Cardiovasc. Surg. 134: 342-350.
Anavekar NS, Williams R, Chong AH 2007 Sweet's syndrome in an Australian hospital: a retrospective analysis. Australas. J. Dermatol. 48: 161-164. *
Anderson VP, Jack S, Monchy D, Hem N, Hok P, Bailey KB, Gibson RS 2008 Co-existing micronutrient deficiencies among stunted Cambodian infants and toddlers. Asia Pac. J. Clin. Nutr. 17: 72-79.
Antebi H, Mansoor O, Ferrier C, Tetegan M, Morvan C, Rangaraj J, Alcindor LG 2004 Liver function and plasma antioxidant status in intensive care unit patients requiring total parenteral nutrition: comparison of 2 fat emulsions. JPEN J. Parenter. Enteral Nutr. 28: 142-148. *
Aoki H, Nakamura K, Yoshimatsu Y, Tsuda Y, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y 2007 Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig. Dis. Sci. 52: 1427-1433. *
Arvidson NG, Larsen A, Aaseth J, Larsson A 2007 Short-term effects of the TNFalpha antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis. Scand. J. Clin. Lab. Invest. 67: 337-342. *
Asakura H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, Hobara R, Nakano H, Okamura S, Matsueda K, Kashida H, Makiyama K, Hiwatashi N, Kashiwagi K, Hibi T 2001 Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J. Gastroenterol. Hepatol. 16: 763-769. *
Ates A, Kinikli G, Turgay M, Akay G, Tokgoz G 2007 Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin. Rheumatol. 26: 538-545. *
Ates A, Kinikli G, Turgay M, Duman M 2004 The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin. Rheumatol. 23: 421-425. *
Ates A, Turkcapar N, Olmez U, Tiryaki O, Duzgun N, Uguz E, Duman M 2007 Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers. Rheumatol. Int. 27: 715-722. *
Ates Y, Degertekin B, Erdil A, Yaman H, Dagalp K 2008 Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig. Dis. Sci. 53: 2215-2221. *
Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP 2008 Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 200: 1-12.
Aue G, Carroll N, Kressel BR, Hardi R, Horne MK 3rd 2005 Disseminated intravascular coagulation in an ambulatory young woman. J. Lab. Clin. Med. 146: 192-196. *
Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H 2008 Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford) 47: 142-144.
Ayensu WK, Tchounwou PB, McMurray RW 2004 Molecular and cellular mechanisms associated with autoimmune diseases. Int. J. Environ. Res. Public Health 1: 39-73.
Baksh MF, Balding DJ, Vyse TJ, Whittaker JC 2007 Family-based association analysis with ordered categorical phenotypes, covariates and interactions. Genet. Epidemiol. 31: 1-8.
Baksh MF, Balding DJ, Vyse TJ, Whittaker JC 2006 A likelihood ratio approach to family-based association studies with covariates. Ann. Hum. Genet. 70: 131-139. *
Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A, Tiberghien P, Chalopin JM, Saas P, Ducloux D 2006 IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation. J. Am. Soc. Nephrol. 17: 2333-2340.
Bankar RN, Dafe CO, Kohnke A, Babu PS 2006 Ulcerative colitis probably associated with isotretinoin. Indian J. Gastroenterol. 25: 171-172. *
Bannerjee K, Camacho-Hubner C, Babinska K, Dryhurst KM, Edwards R, Savage MO, Sanderson IR, Croft NM 2004 Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J. Pediatr. Gastroenterol. Nutr. 38: 270-275. *
Barnes BH, Borowitz SM, Saulsbury FT, Hellems M, Sutphen JL 2004 Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine. J. Pediatr. Gastroenterol. Nutr. 38: 509-512. *
Barthet M, Lesavre N, Desplats S, Panuel M, Gasmi M, Bernard JP, Dagorn JC, Grimaud JC 2006 Frequency and characteristics of pancreatitis in patients with inflammatory bowel disease. Pancreatology 6: 464-471.
Bason C, Corrocher R, Lunardi C, Puccetti P, Olivieri O, Girelli D, Navone R, Beri R, Millo E, Margonato A, Martinelli N, Puccetti A 2003 Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet 362: 1971-1977. *
Basu A, Devaraj S, Jialal I 2006 Dietary factors that promote or retard inflammation. Arterioscler. Thromb. Vasc. Biol. 26: 995-1001. *
Basu A, Jensen MD, McCann F, Nandy D, Mukhopadhyay D, McConnell JP, Rizza RA 2007 Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes. Endocr. Pract. 13: 147-152.
Bazzichi L, Giuliano T, Rossi A, Mazzoni A, Grazzini T, De Feo F, Giacomelli C, Scatena F, Bombardieri S 2008 Partial remission of refractory RA after adacolumn cytapheresis: a case report. Rheumatol. Int. 28: 295-297. *
Beaven SW, Abreu MT 2004 Biomarkers in inflammatory bowel disease. Curr. Opin. Gastroenterol. 20: 318-327.
Becker H, Weber C, Storch S, Federlin K 1990 Relationship between CD5+ B lymphocytes and the activity of systemic autoimmunity. Clin. Immunol. Immunopathol. 56: 219-225.
Bell SA, Faust H, Schmid A, Meurer M 1998 Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. Clin. Exp. Immunol. 113: 327-332. *
Benazzato L, D'Inca R, Grigoletto F, Perissinotto E, Medici V, Angriman I, Sturniolo GC 2004 Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig. Liver Dis. 36: 461-466.
Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T 2006 Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 54: 3782-3789. *
Bergstrom JP, Helander A 2008 HPLC evaluation of clinical and pharmacological factors reported to cause false-positive carbohydrate-deficient transferrin (CDT) levels. Clin. Chim. Acta 389: 164-166. *
Bernatsky S, Ramsey-Goldman R, Lachance S, Pineau CA, Clarke AE 2006 Lymphoma in a patient with systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2: 570-574. *
Berni Canani R, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R 2008 Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig. Liver Dis. 40: 547-553.
Bernstein M, Irwin S, Greenberg GR 2005 Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am. J. Gastroenterol. 100: 2031-2035. *
Berrahmoune H, Herbeth B, Lamont JV, Lambert D, Blankenberg S, Tiret L, Fitzgerald PS, Siest G, Visvikis-Siest S 2007 Association of classical and related inflammatory markers with high-sensitivity C-reactive protein in healthy individuals: results from the Stanislas cohort. Clin. Chem. Lab. Med. 45: 1339-1346.
Berrahmoune H, Herbeth B, Siest G, Visvikis-Siest S 2007 Heritability of serum hs-CRP concentration and 5-year changes in the Stanislas family study: association with apolipoprotein E alleles. Genes Immun. 8: 352-359. *
Berres ML, Schnyder B, Yagmur E, Inglis B, Stanzel S, Tischendorf JJ, Koch A, Winograd R, Trautwein C, Wasmuth HE 2008 Longitudinal monocyte human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis. Liver Int. Sep 15 [Epub ahead of print].
Bertrand-Thiebault C, Berrahmoune H, Thompson A, Marie B, Droesch S, Siest G, Foernzler D, Visvikis-Siest S 2008 Genetic polymorphism of CYP2C19 gene in the Stanislas cohort. A link with inflammation. Ann. Hum. Genet. 72: 178-183. *
Bessa SS, Hamdy SM, Ali EM 2007 Haptoglobin gene polymorphism in type 2 diabetic patients with and without nephropathy: an Egyptian study. Eur. J. Intern. Med. 18: 489-495.
Bevelacqua V, Libra M, Mazzarino MC, Gangemi P, Nicotra G, Curatolo S, Massimino D, Plumari A, Merito P, Valente G, Stivala F, La Greca S, Malaponte G 2006 Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. Int. J. Mol. Med. 18: 415-423. *
Bhat YM, Papachristou GI, Park JS, Lamb J, Slivka A, Whitcomb DC 2007 Gunctional polymorphisms of the GSTT-1 gene do not predict the severity of acute pancreatitis in the United States. Pancreatology 7: 180-186.
Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhubl S, Tan WA, Resar JR, Almahameed A, Abdel-Latif A, Tang HW, Brennan D, McErlean E, Hazen SL, Topol EJ 2007 Peroxisome proliferator-activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization - results of the PPAR study. Am. Heart J. 154: 137-143. *
Biro E, Nieuwland R, Tak PP, Pronk LM, Schaap MC, Sturk A, Hack CE 2007 Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann. Rheum. Dis. 66: 1085-1092. *
Bitton A, Dobkin P, Edwardes MD, Sewitch M, Meddings J, Rawal S, Cohen A, Vermeire S, Dufresne L, Franchimont D, Wild GE 2008 Predicting relapse in Crohn's disease: a biopsychosocial model. Gut Apr 7 [Epub ahead of print].
Bjerregaard LT, Nederby NJ, Fredholm L, Brandslund I, Munkholm P, Hey H 2002 Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 37: 62-67.
Blankenberg-Sprenkels SH, Fielder M, Feltkamp TE, Tiwana H, Wilson C, Ebringer A 1998 Antibodies to Klebsiella pneumoniae in Dutch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis. J. Rheumatol. 25: 743-747.
Blann AD, Babbs C, Neuberger JM 1992 Endothelial cell damage in primary biliary cirrhosis: influence of cholestasis and immunological mechanisms. Clin. Exp. Immunol. 90: 88-92. *
Blaschke F, Spanheimer R, Khan M, Law RE 2006 Vascular effects of TZDs: new implications. Vascul. Pharmacol. 45: 3-18.
Blaschke F, Takata Y, Caglayan E, Collins A, Tontonoz P, Hsueh WA, Tangirala RK 2006 A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ. Res. 99: e88-e99. *
Bleie O, Semb AG, Grundt H, Nordrehaug JE, Vollset SE, Ueland PM, Nilsen DW, Bakken AM, Refsum H, Nygard OK 2007 Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J. Intern. Med. 262: 244-253. *
Blick SK, Curran MP 2007 Certolizumab pegol in Crohn's disease. BioDrugs 21: 195-201.
Block G, Jensen CD, Norkus EP, Dalvi TB, Wong LG, McManus JF, Hudes ML 2007 Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: a cross-sectional study. Nutr. J. 6: 30. *
Bodur H, Ataman S, Akbulut L, Evcik D, Kavuncu V, Kaya T, Gunaydin R, Kuran B, Kotevoglu N, Bal A, Aydog E, Altay Z, Ugurlu H, Kocabas H, Olmez N, Yazgan P, Gursoy S, Madenci E, Ozel S, Delialioglu SU 2008 Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. Clin. Rheumatol. 27: 1119-1125. *
Boehm D, Krzystek-Korpacka M, Neubauer K, Matusiewicz M, Berdowska I, Zielinski B, Paradowski L, Gamian A 2008 Paraoxonase-1 status in Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. Jul 14 [Epub ahead of print].
Bogdanski P, Pupek-Musialik D, Dytfeld J, Lacinski M, Jablecka A, Jakubowski H 2008 Plasma homocysteine is a determinant of tissue necrosis factor-alpha in hypertensive patients. Biomed. Pharmacother. 62: 360-365.
Bokarewa MI, Jin T, Tarkowski A 2003 Intraarticular release and accumulation of defensins and bactericidal/permeability-increasing protein in patients with rheumatoid arthritis. J. Rheumatol. 30: 1719-1724.
Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, Savage C, Pusey C, Jayne D 2004 Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 15: 717-721. *
Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, Wilkinson IB 2004 Infliximab improves endothelial dysfunction in systemic vasculitis. A model of vascular inflammation. Circulation 109: 1718-1723. *
Borman P, Babaoglu S, Gur G, Bingol S, Bodur H 2008 Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin. Rheumatol. 27: 443-447. *
Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Nurmohamed MT 2008 Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J. Rheumatol. Sep 1 [Epub ahead of print].
Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, Ferraccioli G 2008 TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin. Rheumatol. 27: 833-839. *
Bossa F, Latiano A, Rossi L, Magnani M, Palmieri O, Dallapiccola B, Serafini S, Damonte G, De Santo E, Andriulli A, Annese V 2008 Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am. J. Gastroenterol. Aug 21 [Epub ahead of print]. *
Bottazzi B, Garlanda C, Salvatori G, Jeannin P, Manfredi A, Mantovani A 2006 Pentraxins as a key component of innate immunity. Curr. Opin. Immunol. 18: 10-15.
Bradley JD, Dmitrienko AA, Kivitz AJ, Gluck OS, Weaver AL, Wiesenhutter C, Myers SL, Sides GD 2005 A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J. Rheumatol. 32: 417-423.
Brand S, Crispin A 2007 C-reactive protein polymorphism and Crohn's disease: authors' reply. Aliment. Pharmacol. Ther. 25: 520-521.
Brant PE, Kopke-Aguiar L, Shigueoka DC, Sales D, D'Ippolito G, Kouyoumdjian M, Borges DR 2008 Anicteric cholangiopathy in schistosomiasis patients. Acta Trop. Jun 11 [Epub ahead of print].
Branten AJ, Swinkels DW, Klasen IS, Wetzels JF 2004 Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. Nephrol. Dial. Transplant. 19: 2754-2760. *
Brechmann T, Heyer C, Schmiegel W 2007 Methotrexate-induced pneumonitis in a woman with Crohn's disease. Dtsch. Med. Wochenschr. 132: 1759-1762.
Bremner A, Roked S, Robinson R, Phillips I, Beattie M 2005 Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. 94: 1855-1858. *
Brennan MT, Sankar V, Leakan RA, Grisius MM, Collins MT, Fox PC, Baum BJ, Pillemer SR 2003 Sex steroid hormones in primary Sjogren's syndrome. J. Rheumatol. 30: 1267-1271.
Brenol CV, Monticielo OA, Xavier RM, Brenol JC 2007 Rheumatoid arthritis and atherosclerosis. Rev. Assoc. Med. Bras. 53: 465-470.
Broedl UC, Schachinger V, Lingenhel A, Lehrke M, Stark R, Seibold F, Goke B, Kronenberg F, Parhofer KG, Konrad-Zerna A 2007 Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13: 391-397. *
Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, Dewitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF 2008 A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann. Oncol. 19: 1340-1346.
Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS, VON Feldt JM 2007 Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J. Rheumatol. 34: 740-746.
Brown SJ, Abreu MT 2005 Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease. Curr. Opin. Drug Discov. Devel. 8: 160-168.
Browning LM, Krebs JD, Moore CS, Mishra GD, O'connell MA, Jebb SA 2007 The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes. Metab. 9: 70-80. *
Brucato A, Maestroni S, Cumetti D, Thiella G, Alari G, Brambilla G, Imazio M, Doria A, Palmieri G, Adler Y 2008 Recurrent pericarditis: infectious or autoimmune? Autoimmun. Rev. Aug 12 [Epub ahead of print].
Bruce WR, Cirocco M, Giacca A, Kim YI, Marcon N, Minkin S 2005 A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, insulin resistance and colonic inflammation. Br. J. Cancer 93: 639-646.
Bruining DH, Loftus EV 2007 Current and future diagnostic approaches: from serologies to imaging. Curr. Gastroenterol. Rep. 9: 489-496.
Bruining DH, Loftus EV 2006 Evolving diagnostic strategies for inflammatory bowel disease. Curr. Gastroenterol. Rep. 8: 478-485.
Brunkhorst R, Eberhardt OK, Haubitz M, Brunkhorst FM 2000 Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection. Intensive Care Med. 26 Suppl. 2: S199-S201.
Buchman AL, Miller FH, Wallin A, Chowdhry AA, Ahn C 2004 Videocapsule endoscopy versus barium contrast studies for the diagnosis of Crohn's disease recurrence involving the small intestine. Am. J. Gastroenterol. 99: 2171-2177. *
Buckingham RE 2005 Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol. Res. 33: 167-170.
Burkhardt Soares S, Fehr A, Brandt AS, Roth S 2007 Retroperitoneal fibrosis. Aktuelle. Urol. 38: 221-231.
Burns T, Maciejewski SR, Hamilton WR, Zheng M, Mooss AN, Hilleman DE 2007 Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio. Pharmacotherapy 27: 633-638.
Buttenschoen K, Schneider ME, Utz K, Kornmann M, Beger HG, Carli Buttenschoen D 2008 Effect of major abdominal surgery on endotoxin release and expression of Toll-like receptors 2/4. Langenbecks Arch. Surg. Jun 11 [Epub ahead of print]. *
Cacheux W, Seksik P, Lemann M, Marteau P, Nion-Larmurier I, Afchain P, Daniel F, Beaugerie L, Cosnes J 2008 Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am. J. Gastroenterol. 103: 637-642. *
Cagatay Y, Gul A, Cagatay A, Kamali S, Karadeniz A, Inanc M, Ocal L, Aral O, Konice M 2007 Adult-onset Still's disease. Int. J. Clin. Pract. May 18 [Epub ahead of print].
Cai X, Wong YF, Zhou H, Xie Y, Liu ZQ, Jiang ZH, Bian ZX, Xu HX, Liu L 2006 The comparative study of Sprague-Dawley and Lewis rats in adjuvant-induced arthritis. Naunyn. Schmiedebergs. Arch. Pharmacol. 373: 140-147. *
Cakal B, Akoz AG, Ustundag Y, Yalinkilic M, Ulker A, Ankarali H 2008 Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig. Dis. Sci. Aug 21 [Epub ahead of print]. *
Calderon-Garciduenas L, Villarreal-Calderon R, Valencia-Salazar G, Henriquez-Roldan C, Gutierrez-Castrellon P, Torres-Jardon R, Osnaya-Brizuela N, Romero L, Torres-Jardon R, Solt A, Reed W 2008 Systemic inflammation, endothelial dysfunction, and activation in clinically healthy children exposed to air pollutants. Inhal. Toxicol. 20: 499-506.
Callea F, Gregorini G, Sinico A, Gonzales G, Bossolasco M, Salvidio G, Radice A, Tira P, Candiano G, Rossi G, Petti A, Ravera G, Ghiggeri G, Gusmano R 1997 alpha 1-Antitrypsin (AAT) deficiency and ANCA-positive systemic vasculitis: genetic and clinical implications. Eur. J. Clin. Invest. 27: 696-702.
Calvo-Alen J, Alarcon GS, Tew MB, Tan FK, McGwin G Jr, Fessler BJ, Vila LM, Reveille JD 2006 Systemic lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events. Arthritis Rheum. 54: 1940-1945. *
Camilleri M 2005 GIH clinical research update: 2004-2005. Clin. Gastroenterol. Hepatol. 3: 1161-1166.
Caminha MD, Diniz AD, Falbo AR, Arruda IK, Serva VB, Albuquerque LL, Lola MM, Ebrahim GJ 2008 Serum retinol concentrations in hospitalized severe protein-energy malnourished children. J. Trop. Pediatr. 54: 248-252.
Campbell S, Travis S, Jewell D 2005 Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur. J. Gastroenterol. Hepatol. 17: 79-84.
Campos J, Gonzalez-Quintela A, Quinteiro C, Gude F, Perez LF, Torre JA, Vidal C 2005 The -159C/T polymorphism in the promoter region of the CD14 gene is associated with advanced liver disease and higher serum levels of acute-phase proteins in heavy drinkers. Alcohol. Clin. Exp. Res. 29: 1206-1213. *
Caorsi C, Pineda F, Munoz C 2008 Pravastatin immunomodulates IL-6 and C-reactive protein, but not IL-1 and TNF-alpha, in cardio-pulmonary bypass. Eur. Cytokine Netw. 19: 99-103.
Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM 2006 Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol. Int. 26: 209-214. *
Carrero JJ, Fonolla J, Marti JL, Jimenez J, Boza JJ, Lopez-Huertas E 2007 Intake of fish oil, oleic acid, folic acid, and vitamins B-6 and E for 1 year decreases plasma C-reactive protein and reduces coronary heart disease risk factors in male patients in a cardiac rehabilitation program. J. Nutr. 137: 384-390. *
Carroll L, Hannawi S, Marwick T, Thomas R 2006 Rheumatoid arthritis: links with cardiovascular disease and the receptor for advanced glycation end products. Wien. Med. Wochenschr. 156: 42-52.
Carroll MC, Prodeus AP 1998 Linkages of innate and adaptive immunity. Curr. Opin. Immunol. 10: 36-40.
Carvalho JF, Hanaoka B, Szyper-Kravitz M, Shoenfeld Y 2007 C-reactive protein and its implications in systemic lupus erythematosus. Acta Reumatol. Port. 32: 317-322.
Casas M, Mora J, Fort E, Aracil C, Busquets D, Galter S, Jauregui CE, Ayala E, Cardona D, Gich I, Farre A 2007 Total enteral nutrition vs. total parenteral nutrition in patients with severe acute pancreatitis. Rev. Esp. Enferm. Dig. 99: 264-269.
Casimiro L, Barnsley L, Brosseau L, Milne S, Robinson V, Tugwell P, Wells G, Casimiro L 2005 Acupuncture and electroacupuncture for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 4: CD003788. *
Caspi D, Anouk M, Golan I, Paran D, Kaufman I, Wigler I, Levartovsky D, Litinsky I, Elkayam O 2006 Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. Arthritis Rheum. 55: 53-56. *
Celinska-Lowenhoff M, Undas A 2004 Nonlipid effects of fibrates. Przegl. Lek. 61: 99-101.
Chae SC, Park YR, Shim SC, Yoon KS, Chung HT 2004 The polymorphisms of Th1 cell surface gene Tim-3 are associated in a Korean population with rheumatoid arthritis. Immunol. Lett. 95: 91-95.
Chae SC, Park YR, Song JH, Shim SC, Yoon KS, Chung HT 2005 The polymorphisms of Tim-1 promoter region are associated with rheumatoid arthritis in a Korean population. Immunogenetics 56: 696-701. *
Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R 2006 Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin. Gastroenterol. Hepatol. 4: 882-887.
Chen HY, Wu KD, Chen YM 2006 Vasculitis-related Wunderlich's syndrome treated without surgical intervention. Clin. Nephrol. 66: 291-296.
Cheung YF, Huang GY, Chen SB, Liu XQ, Xi L, Liang XC, Huang MR, Chen S, Huang LS, Liu XQ, Chan KW, Lau YL 2008 Inflammatory gene polymorphisms and susceptibility to Kawasaki disease and its arterial sequelae. Pediatrics 122: e608-e614. *
Chiarello PG, Penaforte FR, Japur CC, Souza CD, Vannucchi H, Troncon LE 2008 Increased folate Intake with no changes in serum homocysteine and decreased levels of C-reactive protein in patients with inflammatory bowel diseases. Dig. Dis. Sci. Jul 17 [Epub ahead of print]. *
Chiarla C, Giovannini I, Siegel JH 2008 Patterns of correlation of plasma ceruloplasmin in sepsis. J. Surg. Res. 144: 107-110.
Chikazawa H, Nishiya K, Matsumori A, Hashimoto K 2000 Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases. J. Clin. Immunol. 20: 279-286. *
Cho SE, Sook Hong K, Shin GJ, Chung WS 2006 The methylenetetrahydrofolate reductase C677T gene mutation is associated with hyperhomocysteinemia, cardiovascular disease and plasma B-type natriuretic peptide levels in Korea. Clin. Chem. Lab. Med. 44: 1070-1075. *
Choi KH, Lee EB, Yoo CD, Baek HJ, Kang SW, Shin KC, Lee YJ, Kim HA, Jeon JH, Kim CW, Shin DM, Kim IG, Son YW 2005 Clinical significance of anti-filaggrin antibody recognizing uncitrullinated filaggrin in rheumatoid arthritis. Exp. Mol. Med. 37: 546-552. *
Chopra P, Gulwani H 2007 Pathology and pathogenesis of rheumatic heart disease. Indian J. Pathol. Microbiol. 50: 685-697.
Chouhan S, Gahlot S, Pokharna RK, Mathur KC, Saini K, Pal M 2006 Severity and extent of ulcerative colitis: role of C-reactive protein. Indian J. Gastroenterol. 25: 46-47. *
Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, Kim SH, Park HS, Suh CH 2007 Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 27: 461-466. *
Chung CP, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A, Linton MF, Fazio S, Stein CM 2007 Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. J. Rheumatol. 34: 1849-1854.
Cohen RD 2002 Evolving medical therapies for ulcerative colitis. Curr. Gastroenterol. Rep. 4: 497-505.
Colombel JF, Solem CA, Sandborn WJ, Booya F, Loftus EV, Harmsen WS, Zinsmeister AR, Bodily KD, Fletcher JG 2006 Quantitative measurement and visual assessment of ileal Crohn's disease activity by CT enterography: correlation with endoscopic severity and C-reactive protein. Gut 55: 1561-1567. *
Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lemann M, Mary JY; Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID) 2006 A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm. Bowel Dis. 12: 551-557. *
Cosen-Binker LI, Binker MG, Cosen R, Negri G, Tiscornia O 2006 Relaxin prevents the development of severe acute pancreatitis. World J. Gastroenterol. 12: 1558-1568. *
Courivaud C, Ferrand C, Deschamps M, Tiberghien P, Chalopin JM, Duperrier A, Saas P, Ducloux D 2006 No evidence of association between NOD2/CARD15 gene polymorphism and atherosclerotic events after renal transplantation. Transplantation 81: 1212-1215.
Cronstein BN 2007 Interleukin-6 - a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull. N.Y.U. Hosp. Jt. Dis. 65 Suppl. 1: S11-S15. *
D'Haens G, Hlavaty T 2004 Advances in medical therapy for Crohn's disease. Curr. Gastroenterol. Rep. 6: 496-505.
Dambrauskas Z, Gulbinas A, Pundzius J, Barauskas G 2007 Value of routine clinical tests in predicting the development of infected pancreatic necrosis in severe acute pancreatitis. Scand. J. Gastroenterol. 42: 1256-1264. *
Damsgaard CT, Frokiaer H, Andersen AD, Lauritzen L 2008 Fish oil in combination with high or low intakes of linoleic acid lowers plasma triacylglycerols but does not affect other cardiovascular risk markers in healthy men. J. Nutr. 138: 1061-1066. *
Damsgaard CT, Lauritzen L, Kjaer TM, Holm PM, Fruekilde MB, Michaelsen KF, Frokiaer H 2007 Fish oil supplementation modulates immune function in healthy infants. J. Nutr. 137: 1031-1036. *
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V 2004 C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350: 1387-1397. *
Das UN 2008 Can endogenous lipid molecules serve as predictors and prognostic markers of coronary heart disease? Lipids Health Dis. 7: 19. *
Dasu MR, Devaraj S, Du Clos TW, Jialal I 2007 Biological effects of C-reactive protein are not due to endotoxin contamination: evidence from Toll like receptor 4 knock-down human aortic endothelial cells. J. Lipid Res. 48: 509-512. *
Davis MC, Zautra AJ, Younger J, Motivala SJ, Attrep J, Irwin MR 2008 Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav. Immun. 22: 24-32.
Dayer E, Dayer JM, Roux-Lombard P 2007 Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat. Clin. Pract. Rheumatol. 3: 512-520. *
de Carvalho EG, da Rosa Utiyama SR, da Silva Kotze LM, de Messias Reason IT 2007 Serum mannan-binding lectin levels in patients with celiac disease: an analysis of clinical and autoimmune features. Dig. Dis. Sci. 52: 2145-2151. *
de Fonclare AL, Khosrotehrani K, Aractingi S, Duriez P, Cosnes J, Beaugerie L 2007 Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease. Arch. Dermatol. 143: 744-748.
de Jong NS, Leach ST, Day AS 2006 Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflamm. Bowel Dis. 12: 566-572. *
De Leeuw K, Sanders JS, Stegeman CA, Smit AJ, Kallenberg C, Bijl M 2005 Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann. Rheum. Dis. 64: 753-759. *
de Luis DA, Gonzalez Sagrado M, Vallejo LA, Gil Carcedo LM, Izaola O, Cuellar L, Terroba MC, Aller R 2007 Influence of G308A polymorphism of tumor necrosis factor-alpha gene on inflammatory markers in postsurgical head and neck cancer patients with early enteral nutrition. Nutrition 23: 529-532.
De Matos V, Russo PA, Cohen AB, Mamula P, Baldassano RN, Piccoli DA 2008 Frequency and clinical correlations of granulomas in children with Crohn disease. J. Pediatr. Gastroenterol. Nutr. 46: 392-398.
de Saussure P, Soravia C, Morel P, Hadengue A 2005 Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis. Aliment. Pharmacol. Ther. 22: 203-208. *
de Seny D, Fillet M, Ribbens C, Maree R, Meuwis MA, Lutteri L, Chapelle JP, Wehenkel L, Louis E, Merville MP, Malaise M 2008 Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin. Chem. 54: 1066-1075. *
Del Val Del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E 2006 Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin. Exp. Rheumatol. 24: 281-286.
Denis MA, Reenaers C, Fontaine F, Belaiche J, Louis E 2007 Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm. Bowel Dis. 13: 1100-1105. *
Dentener MA, Creutzberg EC, Pennings HJ, Rijkers GT, Mercken E, Wouters EF 2008 Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration Feb 15 [Epub ahead of print].
Desai D, Faubion WA, Sandborn WJ 2007 Review article: biological activity markers in inflammatory bowel disease. Aliment. Pharmacol. Ther. 25: 247-255. *
Dessein PH, Joffe BI 2006 Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum. 54: 2765-2775. *
Detopoulou P, Panagiotakos DB, Antonopoulou S, Pitsavos C, Stefanadis C. 2008 Dietary choline and betaine intakes in relation to concentrations of inflammatory markers in healthy adults: the ATTICA study. Am. J. Clin. Nutr. 87: 424-430. *
Deutsch L 2007 Evaluation of the effect of neptune krill oil on chronic inflammation and arthritic symptoms. J. Am. Coll. Nutr. 26: 39-48. *
Devaraj S, Kasim-Karakas S, Jialal I 2006 The effect of weight loss and dietary fatty acids on inflammation. Curr. Atheroscler. Rep. 8: 477-486.
Dichi I, Frenhane P, Dichi JB, Correa CR, Angeleli AY, Bicudo MH, Rodrigues MA, Victoria CR, Burini RC 2000 Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis. Nutrition 16: 87-90.
Dickey W 2007 A case of sequential development of celiac disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 463-467. *
Dideberg V, Louis E, Farnir F, Bertoli S, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Bours V 2006 Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet. Genomics 16: 369-373.
Dideberg V, Theatre E, Farnir F, Vermeire S, Rutgeerts P, Vos MD, Belaiche J, Franchimont D, Gossum AV, Louis E, Bours V 2006 The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet. Genomics 16: 727-734.
Dimitrov JD, Roumenina LT, Doltchinkova VR, Vassilev TL 2007 Iron ions and haeme modulate the binding properties of complement subcomponent C1q and of immunoglobulins. Scand. J. Immunol. 65: 230-239. *
Dinarello CA 2005 Anti-cytokine therapy from the bench to the bedside. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 84-86. *
Ding C, Jones G 2006 Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev. Recent Clin. Trials 1: 193-200.
Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W 2008 Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 168: 1340-1349.
Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB 2004 Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment. Pharmacol. Ther. 20: 615-621. *
Donato AJ, Black AD, Jablonski KL, Gano LB, Seals DR 2008 Aging is associated with greater nuclear NFkappaB, reduced IkappaBalpha and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell Sep 8 [Epub ahead of print].
Dorn SD, Sandler RS 2007 Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am. J. Gastroenterol. 102: 662-667. *
Downey DG, Martin SL, Dempster M, Moore JE, Keogan MT, Starcher B, Edgar J, Bilton D, Elborn JS 2007 The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr. Pulmonol. 42: 216-220.
Du Clos TW, Mold C 2004 C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol. Res. 30: 261-278.
Dufek M, Hamanova M, Lokaj J, Goldemund D, Rektorova I, Michalkova Z, Sheardova K, Rektor I 2008 Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat. Disord. Jul 29 [Epub ahead of print].
Edwards CJ, Cooper C 2006 Early environmental factors and rheumatoid arthritis. Clin. Exp. Immunol. 143: 1-5. *
Efrat B, Iris G, Wang H, Eitan S, Yona K 2006 A subgroup of first-degree relatives of Crohn's disease patients shows a profile of inflammatory markers in the blood which is more typical of Crohn's disease patients than of normal individuals. Mediators Inflamm. 2006: 74785. *
Eivindson M, Gronbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, Dahlerup JF 2007 The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease. Scand. J. Gastroenterol. 42: 464-470. *
Eklund C, Huttunen R, Syrjanen J, Laine J, Vuento R, Hurme M 2006 Polymorphism of the C-reactive protein gene is associated with mortality in bacteraemia. Scand. J. Infect. Dis. 38: 1069-1073. *
Ekstrom M, Silveira A, Bennermo M, Eriksson P, Tornvall P 2007 Coagulation factor VII and inflammatory markers in patients with coronary heart disease. Blood Coagul. Fibrinolysis 18: 473-477.
El Miedany YM, Baddour M, Ahmed I, Fahmy H 2005 Sjogren's syndrome: concomitant H. pylori infection and possible correlation with clinical parameters. Joint Bone Spine 72: 135-141.
Eleftheriadis T, Kartsios C, Yiannaki E, Kazila P, Antoniadi G, Liakopoulos V, Markala D 2008 Chronic inflammation and T cell zeta-chain downregulation in hemodialysis patients. Am. J. Nephrol. 28: 152-157.
Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP 2005 Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 12: 255-269.
Emery P, Gabay C, Kraan M, Gomez-Reino J 2007 Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol. Int. 27: 793-806. *
Endres M 2006 Statins: potential new indications in inflammatory conditions. Atheroscler. Suppl. 7: 31-35.
Ercan E, Tengiz I, Altuglu I, Sekuri C, Aliyev E, Ercan HE, Akin M 2004 Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia. Kardiol. Pol. 60: 454-458.
Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A, Berge RK, Hausken T 2005 Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand. J. Gastroenterol. 40: 1058-1065. *
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ 2004 C-reactive protein and the risk of incident colorectal cancer. JAMA 291: 585-590. *
Ernestam S, Hafstrom I, Werner S, Carlstrom K, Tengstrand B 2007 Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function. J. Rheumatol. 34: 1451-1458.
Ernstgard L, Iregren A, Sjogren B, Johanson G 2006 Acute effects of exposure to vapours of dioxane in humans. Hum. Exp. Toxicol. 25: 723-729.
Espe K, Galler A, Raila J, Kiess W, Schweigert FJ 2007 High-normal C-reactive protein levels do not affect the vitamin A transport complex in serum of children and adolescents with type 1 diabetes. Pediatr. Res. 62: 741-745. *
Etherington C, Hall M, Conway S, Peckham D, Denton M 2008 Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis. J. Antimicrob. Chemother. 61: 425-427.
Evensen KJ, Swaak TJ, Nossent JC 2007 Increased ferritin response in adult Still's disease: specificity and relationship to outcome. Scand. J. Rheumatol. 36: 107-110.
Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, Daures JP, Jorgensen C 2008 Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin. Exp. Immunol. 153: 188-195.
Fedorak RN 2004 Conservative approach to severe ulcerative colitis. Dig. Liver Dis. 36: 4-6. *
Fegan PG, Shore AC, Mawson D, Tooke JE, Macleod KM 2005 Microvascular endothelial function in subjects with type 2 diabetes and the effect of lipid-lowering therapy. Diabet. Med. 22: 1670-1676. *
Fellah H, Omar S, Feki M, Abderrahim E, Abdallah TB, Massy ZA, Lacour B, Maiz HB, Kaabachi N, Mebazaa A 2008 Is serum transthyretin a reliable marker of nutritional status in patients with end-stage renal disease? Clin. Biochem. 41: 493-497.
Fernandez-Real JM, Broch M, Vendrell J, Ricart W 2003 Insulin resistance, inflammation, and serum fatty acid composition. Diabetes Care 26: 1362-1368. *
Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes K, Rutgeerts P 2007 Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm. Bowel Dis. 13: 123-128. *
Figueredo MA, Rodriguez A, Ruiz-Yague M, Romero M, Fernandez-Cruz A, Gomez-de la Concha E, Patino R 2006 Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J. Rheumatol. 33: 1980-1986.
Filik L, Dagli U, Ulker A 2006 C-reactive protein and monitoring the activity of Crohn's disease. Adv. Ther. 23: 655-662.
Firuzi O, Spadaro A, Spadaro C, Riccieri V, Petrucci R, Marrosu G, Saso L 2008 Protein oxidation markers in the serum and synovial fluid of psoriatic arthritis patients. J. Clin. Lab. Anal. 22: 210-215.
Florin TH, Paterson EW, Fowler EV, Radford-Smith GL 2006 Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand. J. Gastroenterol. 41: 306-311. *
Fontana L 2008 Neuroendocrine factors in the regulation of inflammation: excessive adiposity and calorie restriction. Exp. Gerontol. Apr 12 [Epub ahead of print].
Forrest CM, Mackay GM, Stoy N, Stone TW, Darlington LG 2007 Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Br. J. Clin. Pharmacol. 64: 517-526. *
Franchimont D 2007 C-reactive protein: informative or misleading marker of Crohn's disease? Inflamm. Bowel Dis. 13: 501-502. *
Fraser A, Longnecker MP, Lawlor DA 2007 Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 133: 1814-1820. *
Fujioka S, Hamazaki K, Itomura M, Huan M, Nishizawa H, Sawazaki S, Kitajima I, Hamazaki T 2006 The effects of eicosapentaenoic acid-fortified food on inflammatory markers in healthy subjects - a randomized, placebo-controlled, double-blind study. J. Nutr. Sci. Vitaminol. (Tokyo) 52: 261-265. *
Fukuda W, Yamazaki T, Akaogi T, Hayashi H, Kusakabe T, Tsubouchi Y, Kawahito Y, Inoue M, Yoshikawa T 2005 Malnutrition and disease progression in patients with rheumatoid arthritis. Mod. Rheumatol. 15: 104-107.
Fukui H 2005 Relation of endotoxin, endotoxin binding proteins and macrophages to severe alcoholic liver injury and multiple organ failure. Alcohol Clin. Exp. Res. 29: 172S-179S.
Gaipl US, Kuhn A, Sheriff A, Munoz LE, Franz S, Voll RE, Kalden JR, Herrmann M 2006 Clearance of apoptotic cells in human SLE. Curr. Dir. Autoimmun. 9: 173-187.
Gaipl US, Sheriff A, Franz S, Munoz LE, Voll RE, Kalden JR, Herrmann M 2006 Inefficient clearance of dying cells and autoreactivity. Curr. Top. Microbiol. Immunol. 305: 161-176.
Galligan CL, Baig E, Bykerk V, Keystone EC, Fish EN 2007 Distinctive gene expression signatures in rheumatoid arthritis synovial tissue fibroblast cells: correlates with disease activity. Genes Immun. 8: 480-491. *
Garcia-Lazaro JF, Thieringer F, Luth S, Czochra P, Meyer E, Renteria IB, Galle PR, Lohse AW, Herkel J, Kanzler S 2005 Hepatic over-expression of TGF-beta1 promotes LPS-induced inflammatory cytokine secretion by liver cells and endotoxemic shock. Immunol. Lett. 101: 217-222.
Gardinali M, Conciato L, Cafaro C, Crosignani A, Battezzati PM, Agostoni A, Podda M 1998 Complement system is not activated in primary biliary cirrhosis. Clin. Immunol. Immunopathol. 87: 297-303. *
Garred P, Pressler T, Lanng S, Madsen HO, Moser C, Laursen I, Balstrup F, Koch C, Koch C 2002 Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr. Pulmonol. 33: 201-207.
Gelbmann CM 2000 Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease - do we have reliable markers? Inflamm. Bowel Dis. 6: 123-131. *
Gentilucci UV, Caviglia R, Picardi A, Carotti S, Ribolsi M, Galati G, Petitti T, Afeltra A, Cicala M 2005 Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment. Pharmacol. Ther. 21: 1063-1071. *
Gerhardt T, Milz S, Schepke M, Feldmann G, Wolff M, Sauerbruch T, Dumoulin FL 2006 C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J. Gastroenterol. 12: 5495-5500. *
Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, Kooistra T 2004 Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J. Biol. Chem. 279: 16154-1660. *
Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S; Natalizumab Pan-European Study Group 2003 Natalizumab for active Crohn's disease. N. Engl. J. Med. 348: 24-32. *
Gisbert JP, Gonzalez-Lama Y, Mate J 2007 Role of biological markers in inflammatory bowel disease. Gastroenterol. Hepatol. 30: 117-129.
Goertz B, Fassbender WJ, Williams JC, Marzeion AM, Bretzel RG, Stracke H, Berliner MN 2003 Vitamin D receptor genotypes are not associated with rheumatoid arthritis or biochemical parameters of bone turnover in German RA patients. Clin. Exp. Rheumatol. 21: 333-339.
Goggins MG, Goh J, O'Connell MA, Weir DG, Kelleher D, Mahmud N 2001 Soluble adhesion molecules in inflammatory bowel disease. Ir. J. Med. Sci. 170: 107-111.
Goggins MG, Shah SA, Goh J, Cherukuri A, Weir DG, Kelleher D, Mahmud N 2001 Increased urinary nitrite, a marker of nitric oxide, in active inflammatory bowel disease. Mediators Inflamm. 10: 69-73. *
Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, et al 2006 Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 355: 581-592. *
Goncalves M, D'Almeida V, Guerra-Shinohara EM, Galdieri LC, Len CA, Hilario MO 2007 Homocysteine and lipid profile in children with juvenile idiopathic arthritis. Pediatr. Rheumatol. Online J. 5: 2. *
Gonzalez S, Rodrigo L, Martinez-Borra J, Lopez-Vazquez A, Fuentes D, Nino P, Cadahia V, Saro C, Dieguez MA, Lopez-Larrea C 2003 TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease. Am. J. Gastroenterol. 98: 1101-1016. *
Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Pineiro A, Garcia-Porrua C, Miranda-Filloy JA, Ollier WE, Martin J, Llorca J 2007 HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 57: 125-132. *
Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, Gonzalez-Juanatey C, De Matias JM, Martin J, Redelinghuys M, Woodiwiss AJ, Norton GR, Dessein PH 2008 High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin. Exp. Rheumatol. 26: 596-603.
Gorska A, Urban M, Pietrewicz E, Gorski S 2006 Composition of linoleic and arachidonic acids in phosphatidylcholine of erythrocytes membrane and IL-6 and TNF-alpha in serum and C-reactive protein concentration in children with juvenile idiopathic arthritis. Pol. Merkur. Lekarski. 21: 551-553.
Goto A, Mukai M, Notoya A, Kohno M 2005 Rheumatoid arthritis complicated with myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis: a case report. Mod. Rheumatol. 15: 118-122.
Greer RM, Buntain HM, Lewindon PJ, Wainwright CE, Potter JM, Wong JC, Francis PW, Batch JA, Bell SC 2004 Vitamin A levels in patients with CF are influenced by the inflammatory response. J. Cyst. Fibros. 3: 143-149.
Greiner A, Plischke H, Kellner H, Gruber R 2005 Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1050: 295-303. *
Grip O, Janciauskiene S, Bredberg A 2008 Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. Br. J. Pharmacol. Sep 22 [Epub ahead of print].
Grivceva Stardelova K, Misevska P, Zdravkovska M, Trajkov D, Serafimoski V 2008 Total parenteral nutrition in treatment of patients with inflammatory bowel disease. Prilozi. 29: 21-43.
Grunewald RW, Fiedler GM, Stockmann F, Schauer A, Muller GA 1997 Unusual diagnosis in recurrent arthritis, erythema nodosum and arrhythmia. Dtsch. Med. Wochenschr. 122: 1516-1520.
Grzymislawski M, Derc K, Sobieska M, Wiktorowicz K 2006 Microheterogeneity of acute phase proteins in patients with ulcerative colitis. World J. Gastroenterol. 12: 5191-5195.
Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J 1997 Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J. Antimicrob. Chemother. 39: 393-400. *
Gul U, Gonul M, Kilic A, Erdem R, Cakmak SK, Gunduz H 2006 Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A. Clin. Ther. 28: 251-254. *
Gullu S, Emral R, Bastemir M, Parkes AB, Lazarus JH 2005 In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis. Eur. J. Endocrinol. 153: 41-48. *
Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M 2006 Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med. J. 99: 1078-1083.
Gustavsson C, Agardh E, Bengtsson B, Agardh CD 2008 TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J. Diabetes Complications 22: 309-316.
Ha JS, Lee JS, Kim HJ, Moon TG, Chang DK, Lee JH, Kim YH, Rhee PL, Kim JJ, Rhee JC 2006 Comparative usefulness of erythrocyte sedimentation rate and C-reactive protein in assessing the severity of ulcerative colitis. Korean J. Gastroenterol. 48: 313-320.
Haas SL, Lohse P, Schmitt WH, Hildenbrand R, Karaorman M, Singer MV, Bocker U 2006 Severe TNF receptor-associated periodic syndrome due to 2 TNFRSF1A mutations including a new F60V substitution. Gastroenterology 130: 172-178. *
Haider DG, Leuchten N, Schaller G, Gouya G, Kolodjaschna J, Schmetterer L, Kapiotis S, Wolzt M 2006 C-reactive protein is expressed and secreted by peripheral blood mononuclear cells. Clin. Exp. Immunol. 146: 533-539. *
Hammana I, Malet A, Costa M, Brochiero E, Berthiaume Y, Potvin S, Chiasson JL, Coderre L, Rabasa-Lhoret R 2007 Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. Diabetes Metab. 33: 213-219.
Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P 2006 Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn�s disease: the CLASSIC-I trial. Gastroenterology 130: 323-333. *
Hanefeld M, Marx N, Pfutzner A, Baurecht W, Lubben G, Karagiannis E, Stier U, Forst T 2007 Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study. J. Am. Coll. Cardiol. 49: 290-297.
Hanriot D, Bello G, Ropars A, Seguin-Devaux C, Poitevin G, Grosjean S, Latger-Cannard V, Devaux Y, Zannad F, Regnault V, Lacolley P, Mertes PM, Hess K, Longrois D 2008 C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb. Haemost. 99: 558-569.
Hansen TK, Thiel S, Knudsen ST, Gravholt CH, Christiansen JS, Mogensen CE, Poulsen PL 2003 Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 88: 4857-4861. *
Hartweg J, Farmer AJ, Holman RR, Neil HA 2007 Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia 50: 250-258. *
Hasegawa M, Nakoshi Y, Muraki M, Sudo A, Kinoshita N, Yoshida T, Uchida A 2007 Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis. J. Orthop. Res. 25: 563-568.
Hashmi S, Zeng QT 2006 Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron. Artery Dis. 17: 699-706.
Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN, Van Dyke TE 2007 Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 179: 7021-7029.
Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjoro K, Aukrust P 2006 Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 44: 1167-1174. *
Hayashi T, Matsumoto I, Muraki Y, Takahashi R, Chino Y, Goto D, Ito S, Tsutsumi A, Sumida T 2005 Clinical characteristics of anti-glucose-6-phosphate isomerase antibody-positive Japanese patients with rheumatoid arthritis. Mod. Rheumatol. 15: 258-263.
Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E, Silbermann-Hoffman O, Kahn MF, Meyer O 1999 SAPHO syndrome: a long-term follow-up study of 120 cases. Semin. Arthritis Rheum. 29: 159-171. *
He R, Shepard LW, Chen J, Pan ZK, Ye RD 2006 Serum amyloid A is an endogenous ligand that differentially induces IL-12 and IL-23. J. Immunol. 177: 4072-4079. *
Heath DI, Cruickshank A, Gudgeon M, Jehanli A, Shenkin A, Imrie CW 1993 Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis. Gut 34: 41-45. *
Hedger SC, Macardle P, Bond MJ, Ahern MJ, Smith MD, Roberts-Thomson PJ 1999 Shared rheumatoid epitope as a risk factor in determining outcome in rheumatoid arthritis. Aust. N. Z. J. Med. 29: 234-238.
Henningsson S, Hakansson A, Westberg L, Baghaei F, Rosmond R, Holm G, Ekman A, Nissbrandt H, Eriksson E 2006 Interleukin-6 gene polymorphism -174G/C influences plasma lipid levels in women. Obesity (Silver Spring) 14: 1868-1873. *
Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B 2008 C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease: results from a prospective population-based study. Gut Jun 19 [Epub ahead of print].
Herrlinger KR, Dittmann R, Weitz G, Wehkamp J, Ludwig D, Schwab M, Stange EF, Fellermann K 2004 Serum procalcitonin differentiates inflammatory bowel disease and self- limited colitis. Inflamm. Bowel Dis. 10: 229-233. *
Hilal MA, Ung CT, Westlake S, Johnson CD 2007 Carboxypeptidase-B activation peptide, a marker of pancreatic acinar injury, but not l-selectin, a marker of neutrophil activation, predicts severity of acute pancreatitis. J. Gastroenterol. Hepatol. 22: 349-354. *
Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G 2007 Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J. Ren. Nutr. 17: 296-304.
Hiraga Y, Yuhki Y, Itoh K, Tadano K, Takahashi Y, Mukai M 2004 Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis. Mod. Rheumatol. 14: 135-142.
Hirohata S, Miura Y, Tomita T, Yoshikawa H, Ochi T, Chiorazzi N 2006 Enhanced expression of mRNA for nuclear factor kappaB1 (p50) in CD34+ cells of the bone marrow in rheumatoid arthritis. Arthritis Res. Ther. 8: R54. *
Hitchon CA, Alex P, Erdile LB, Frank MB, Dozmorov I, Tang Y, Wong K, Centola M, El-Gabalawy HS 2004 A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J. Rheumatol. 31: 2336-2346.
Holdenrieder S, Eichhorn P, Beuers U, Samtleben W, Schoenermarck U, Zachoval R, Nagel D, Stieber P 2006 Nucleosomal DNA fragments in autoimmune diseases. Ann. N. Y. Acad. Sci. 1075: 318-327. *
Holmen N, Lundgren A, Lundin S, Bergin AM, Rudin A, Sjovall H, Ohman L 2006 Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm. Bowel Dis. 12: 447-456. *
Holtkamp W, Stollberg T, Reis HE 1995 Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. J. Clin. Gastroenterol. 20: 123-126.
Hsieh MC, Hsiao JY, Tien KJ, Chang SJ, Lin PC, Hsu SC, Liang HT, Chen HC, Lin SR 2008 The association of endothelial nitric oxide synthase G894T polymorphism with C-reactive protein level and metabolic syndrome in a Chinese study group. Metabolism 57: 1125-1129. *
Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW 2008 Plasma esterases and inflammation in ageing and frailty. Eur. J. Clin. Pharmacol. May 28 [Epub ahead of print].
Huber R, Ditfurth AV, Amann F, Guthlin C, Rostock M, Trittler R, Kummerer K, Merfort I 2007 Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J. Clin. Gastroenterol. 41: 834-838.
Hung YJ, Hsieh CH, Chen YJ, Pei D, Kuo SW, Shen DC, Sheu WH, Chen YC 2007 Insulin sensitivity, proinflammatory markers and adiponectin in young males with different subtypes of depressive disorder. Clin. Endocrinol. (Oxf.) 67: 784-789. *
Hurlimann D, Enseleit F, Ruschitzka F 2004 Rheumatoid arthritis, inflammation, and atherosclerosis. Herz. 29: 760-768.
Hyams JS, Wilson DC, Thomas A, Heuschkel R, Mitton S, Mitchell B, Daniels R, Libonati MA, Zanker S, Kugathasan S; International Natalizumab CD305 Trial Group 2007 Natalizumab therapy for moderate to severe Crohn disease in adolescents. J. Pediatr. Gastroenterol. Nutr. 44: 185-191. *
Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Bambara LM, Triolo G, Ferraccioli G, Valentini G, Lapadula G 2007 Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab due to side effects. Ann. Rheum. Dis. 66: 249-252. *
Igarashi M, Hirata A, Yamaguchi H, Jimbu Y, Tominaga M 2008 Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. J. Atheroscler. Thromb. 15: 34-40.
Iijima S, Iwata M, Otsuka F 1996 Rheological analysis of peripheral blood neutrophils in a patient with cutaneous and arthropathic psoriasis accompanying hypopyon-iridocyclitis. Australas. J. Dermatol. 37 Suppl. 1: S40-S41.
Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M 2008 Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J. Autoimmun. Aug 12 [Epub ahead of print].
Ingram JR, Rhodes J, Evans BK, Thomas GA 2008 Nicotine enemas for active Crohn's colitis: an open pilot study. Gastroenterol. Res. Pract. 2008: 237185. *
Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR 2008 Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J. Rheumatol. 35: 1002-1008.
Ireland R 2005 Association of C-reactive protein with other measures of clinical activity in inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 440. *
Ito S, Yukawa T, Uetake S, Yamauchi M 2007 Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Alcohol Clin. Exp. Res. 31: S83-S87. *
Jacobsen S, Madsen HO, Klarlund M, Jensen T, Skjodt H, Jensen KE, Svejgaard A, Garred P; TIRA Group 2001 The influence of mannose binding lectin polymorphisms on disease outcome in early polyarthritis. J. Rheumatol. 28: 935-942.
Jahnsen J, Falch JA, Mowinckel P, Aadland E 2004 Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand. J. Gastroenterol. 39: 145-153. *
Jansen MC, van Wanrooy S, van Hillegersberg R, Rijken AM, van Coevorden F, Prevoo W, van Gulik TM 2008 Assessment of systemic inflammatory response (SIR) in patients undergoing radiofrequency ablation or partial liver resection for liver tumors. Eur. J. Surg. Oncol. 34: 662-667.
Jehn M, Clark JM, Guallar E 2004 Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27: 2422-2428. *
Jeschke MG, Rensing H, Klein D, Schubert T, Mautes AE, Bolder U, Croner RS 2005 Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats. J. Hepatol. 42: 870-879. *
Jesus AA, Oliveira JB, Aksentijevich I, Fujihira E, Carneiro-Sampaio MM, Duarte AJ, Silva CA 2008 TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept. Eur. J. Pediatr. Apr 12 [Epub ahead of print].
Jia XW, Tian YP, Wang Y, Deng XX, Dong ZN 2007 Correlation of polymorphism in IL-6 gene promoter with BMI, inflammatory factors, and pathogenesis and progression of CHD. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15: 1270-1275.
Jiang S, Xia D, Samols D 2006 Expression of rabbit C-reactive protein in transgenic mice inhibits development of antigen-induced arthritis. Scand. J. Rheumatol. 35: 351-355. *
Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, Baudhuin L, Hanson K, Feagan BG, Harmsen SW, Zinsmeister AR, Helou E, Sandborn WJ 2008 Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. Sep 16 [Epub ahead of print].
Jones PJ, Demonty I, Chan YM, Herzog Y, Pelled D 2007 Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects. Lipids Health Dis. 6: 28. *
Jongbloed SL, Lebre MC, Fraser AR, Gracie JA, Sturrock RD, Tak PP, McInnes IB 2005 Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res. Ther. 8: R15. *
Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE 2008 Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 48: 80-87.
Joos S, Brinkhaus B, Maluche C, Maupai N, Kohnen R, Kraehmer N, Hahn EG, Schuppan D 2004 Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion 69: 131-139.
Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Ampatzidis G, Liapis CD, Alevizos M 2007 The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus. Eur. J. Cardiovasc. Prev. Rehabil. 14: 837-843.
Kajiyama H, Akama H, Yamanaka H, Shoji A, Matsuda Y, Tanaka E, Nakajima A, Terai C, Hara M, Tomatsu T, Saitoh T, Kamatani N 2006 One third of Japanese patients with rheumatoid arthritis use complementary and alternative medicine. Mod. Rheumatol. 16: 355-359. *
Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK 2007 Chios mastic treatment of patients with active Crohn's disease. World J. Gastroenterol. 13: 748-753. *
Kang EW, Nam JY, Yoo TH, Shin SK, Kang SW, Han DS, Han SH 2008 Clinical implications of subclinical hypothyroidism in continuous ambulatory peritoneal dialysis patients. Am. J. Nephrol. 28: 908-913.
Kapitany A, Szabo Z, Lakos G, Aleksza M, Vegvari A, Soos L, Karanyi Z, Sipka S, Szegedi G, Szekanecz Z 2008 Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis. Isr. Med. Assoc. J. 10: 32-36. *
Kaposi Novak P, Schmidt Z 2006 Polymyalgia rheumatica. Orv. Hetil. 147: 1791-1802.
Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, Kouroumalis EA 2001 Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am. J. Gastroenterol. 96: 776-781. *
Kapsoritakis AN, Potamianos SP, Sfiridaki AI, Koukourakis MI, Koutroubakis IE, Roussomoustakaki MI, Manousos ON, Kouroumalis EA 2000 Elevated thrombopoietin serum levels in patients with inflammatory bowel disease. Am. J. Gastroenterol. 95: 3478-3481. *
Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y 2008 Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm. Venereol. 88: 337-340.
Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Kouroumalis EA 2007 The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 19: 789-794.
Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA 2006 Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm. Bowel Dis. 12: 100-105. *
Karoui S, Djebbi S, Boubaker J, Filali A 2006 Predictive factors of failure of intravenous corticoid treatment in acute severe colitis of Crohn's disease and ulcerative colitis. Tunis. Med. 84: 480-486.
Karoui S, Ouerdiane S, Serghini M, Jomni T, Kallel L, Fekih M, Boubaker J, Filali A 2007 Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. Dig. Liver Dis. 39: 1006-1010.
Kasagi S, Kawano S, Nakazawa T, Sugino H, Koshiba M, Ichinose K, Ida H, Eguchi K, Kumagai S 2008 A case of periodic-fever-syndrome-like disorder with lipodystrophy, myositis, and autoimmune abnormalities. Mod. Rheumatol. 18: 203-207. *
Katada Y, Harada Y, Azuma N, Matsumoto K, Terada H, Kudo E, Ishii M, Yamane H, Yamamoto S, Ohshima S, Mima T, Tanaka T, Saeki Y 2006 Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa. Mod. Rheumatol. 16: 256-259. *
Kaya E, Dervisoglu A, Polat C 2007 Evaluation of diagnostic findings and scoring systems in outcome prediction in acute pancreatitis. World J. Gastroenterol. 13: 3090-3094. *
Kayahan H, Akarsu M, Ozcan MA, Demir S, Ates H, Unsal B, Akpinar H 2007 Reticulated platelet levels in patients with ulcerative colitis. Int. J. Colorectal Dis. 22: 1429-1435. *
Kerekes G, Szekanecz Z, Der H, Sandor Z, Lakos G, Muszbek L, Csipo I, Sipka S, Seres I, Paragh G, Kappelmayer J, Szomjak E, Veres K, Szegedi G, Shoenfeld Y, Soltesz P 2008 Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 35: 398-406.
Kerry JE, Marshall C, Griffiths PA, Scott BB, Griffiths G 2003 White cell scanning for inflammatory bowel disease: are biochemical markers useful referral criteria? Nucl. Med. Commun. 24: 1145-1148.
Kessel A, Elias G, Pavlotzky E, Zuckerman E, Rosner I, Toubi E 2007 Anti-C-reactive protein antibodies in chronic hepatitis C infection: correlation with severity and autoimmunity. Hum. Immunol. 68: 844-848.
Khalid S, McGrowder D, Kemp M, Johnson P 2007 The use of soluble transferin receptor to assess iron deficiency in adults with cystic fibrosis. Clin. Chim. Acta 378: 194-200. *
Khalid U, Norman AR, Andreyev HJ 2007 Elevated C-reactive protein levels are not a feature of uncomplicated radiation-induced bowel injury. Eur. J. Cancer Care (Engl.) 16: 346-350.
Khanna D, Wu H, Park G, Gersuk V, Gold RH, Nepom GT, Wong WK, Sharp JT, Reed EF, Paulus HE, Tsao BP 2006 Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis Rheum. 54: 1105-1116. *
Kidd PM 2007 Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern. Med. Rev. 12: 207-227. *
Kim HJ, Kim JS, Han DS, Yang SK, Hahm KB, Lee WI, Kwon SW, Choi JH, Kim WH, Choi KY, Song IS 2005 Granulocyte and monocyte adsorption apheresis in Korean conventional treatment-refractory patients with active ulcerative colitis: a prospective open-label multicenter study. Korean J. Gastroenterol. 45: 34-44.
Kim HR, Kim HS, Park MK, Cho ML, Lee SH, Kim HY 2007 The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand. J. Rheumatol. 36: 259-264.
Kim HR, Kim HY, Lee SH 2006 Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford) 45: 1197-1200. *
Kim HR, Park MK, Cho ML, Yoon CH, Lee SH, Park SH, Leng L, Bucala R, Kang I, Choe J, Kim HY 2007 Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J. Rheumatol. 34: 927-936.
Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, Comaneshter D, Paran D, Wigler I, Levartovsky D, Berliner S, Elkayam O 2007 Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin. Arthritis Rheum. 36: 203-209. *
King GL 2008 The role of inflammatory cytokines in diabetes and its complications. J. Periodontol. 79: S1527-S1534.
Kino T, Rice KC, Chrousos GP 2007 The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur. J. Clin. Invest. 37: 425-433. *
Kirkpantur A, Kahraman S, Genctoy G, Altun B, Abali G, Arici M, Turgan C 2008 The interleukin-10 promoter genotype predicts diastolic dysfunction in maintenance hemodialysis patients. Hemodial. Int. 12: 352-361.
Kiviniemi H, Juvonen T, Makela J 1994 Acute phase response in patients with uncomplicated and complicated endoscopic retrogradic cholangiopancreaticography. HPB Surg. 8: 129-131. *
Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T 2003 Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 101: 545-551. *
Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J 2004 Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J. Rheumatol. 31: 238-242.
Klimiuk PA, Sierakowski S, Latosiewicz R, Skowronski J, Cylwik JP, Cylwik B, Chwiecko J 2005 Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. J. Rheumatol. 32: 1666-1672.
Kobayashi A, Naito S, Enomoto H, Shiomoi T, Kimura T, Obata K, Inoue K, Okada Y 2007 Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch. Pathol. Lab. Med. 131: 563-570.
Koch AK, Bromme S, Wollschlager B, Horneff G, Keyszer G 2008 Musculoskeletal manifestations and rheumatic symptoms in patients with cystic fibrosis (CF) - no observations of CF-specific arthropathy. J. Rheumatol. 35: 1882-1891.
Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B 2008 C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J. Gastroenterol. 14: 85-89. *
Koh SJ, Jang Y, Hyun YJ, Park JY, Song YD, Shin KK, Chae JS, Kim BK, Ordovas JM, Lee JH 2008 The interleukin-6 -572C-->G promoter polymorphism is associated with type 2 diabetes risk in Koreans. Clin. Endocrinol. (Oxf.) Jun 20 [Epub ahead of print].
Komatsuda A, Ohtani H, Wakui H, Chyzh KA, Hatakeyama T, Iwamoto K, Maki N, Kimura T, Hitomi J, Sawada K 2006 Increased serum levels of S100A12 in patients with MPO-ANCA-associated glomerulonephritis. Clin. Nephrol. 66: 315-321.
Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenk�hn T, Parhofer KG, Goke B, Broedl UC 2007 Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur. J. Gastroenterol. Hepatol. 19: 1070-1074.
Korczowski B, Szybist W 2004 Serum procalcitonin and C-reactive protein in children with diarrhoea of various aetiologies. Acta Paediatr. 93: 169-173.
Korolenko TA, Goncharova IA, Anterejkina LI, Levina OA, Korolenko CP 2006 Influence of opiate addiction on liver cell damage of patients with viral hepatitis C. Alaska Med. 49: 75-78.
Kotani K, Sakane N, Sano Y, Saiga K, Tabata M, Kurozawa Y 2007 The peroxisome proliferator-activated receptor gamma2 gene Pro12Ala polymorphism and serum C-reactive protein in general Japanese population. Clin. Chim. Acta 383: 178-179.
Koto T, Nagai N, Mochimaru H, Kurihara T, Izumi-Nagai K, Satofuka S, Shinoda H, Noda K, Ozawa Y, Inoue M, Tsubota K, Oike Y, Ishida S 2007 Eicosapentaenoic acid is anti-inflammatory in preventing choroidal neovascularization in mice. Invest. Ophthalmol. Vis. Sci. 48: 4328-4334.
Kotter I, Wacker A, Koch S, Henes J, Richter C, Engel A, Gunaydin I, Kanz L 2007 Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin. Arthritis Rheum. 37: 189-197. *
Koutroubakis IE, Karmiris K, Makreas S, Xidakis C, Niniraki M, Kouroumalis EA 2006 Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study. Eur. J. Gastroenterol. Hepatol. 18: 421-435.
Kozlowski P, Miller DT, Zee RY, Danik JS, Chasman DI, Lazarus R, Cook NR, Ridker PM, Kwiatkowski DJ 2006 Lack of association between genetic variation in 9 innate immunity genes and baseline CRP levels. Ann. Hum. Genet. 70: 574-586. *
Kraus VB, Stabler TV, Luta G, Renner JB, Dragomir AD, Jordan JM 2007 Interpretation of serum C-reactive protein (CRP) levels for cardiovascular disease risk is complicated by race, pulmonary disease, body mass index, gender, and osteoarthritis. Osteoarthritis Cartilage 15: 966-971.
Kravitz MS, Pitashny M, Shoenfeld Y 2005 Protective molecules - C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J. Clin. Immunol. 25: 582-591. *
Kravitz MS, Shoenfeld Y 2006 Autoimmunity to protective molecules: is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases? Nat. Clin. Pract. Rheumatol. 2: 481-490. *
Krayenbuehl PA, Wiesli P, Schmid M, Schmid C, Ehses JA, Hersberger M, Vetter W, Schulthess G 2007 TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin. Exp. Clin. Endocrinol. Diabetes 115: 322-326.
Krzystek-Korpacka M, Neubauer K, Berdowska I, Boehm D, Zielinski B, Petryszyn P, Terlecki G, Paradowski L, Gamian A 2008 Enhanced formation of advanced oxidation protein products in IBD. Inflamm. Bowel Dis. 14: 794-802.
Kudo-Tanaka E, Ohshima S, Ishii M, Mima T, Matsushita M, Azuma N, Harada Y, Katada Y, Ikeue H, Umeshita-Sasai M, Miyatake K, Saeki Y 2007 Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin. Rheumatol. 26: 1627-1633. *
Kumar N, Armstrong DJ 2008 Cardiovascular disease - the silent killer in rheumatoid arthritis. Clin. Med. 8: 384-387.
Kumar S, Ghoshal UC, Aggarwal R, Saraswat VA, Choudhuri G 2004 Severe ulcerative colitis: prospective study of parameters determining outcome. J. Gastroenterol. Hepatol. 19: 1247-1252. *
Kunihiro K, Hata J, Manabe N, Mitsuoka Y, Tanaka S, Haruma K, Chayama K 2007 Predicting the need for surgery in Crohn's disease with contrast harmonic ultrasound. Scand. J. Gastroenterol. 42: 577-585. *
Kuo HL, Chou CY, Liu YL, Yang YF, Huang CC, Lin HH 2008 Reduction of pro-inflammatory cytokines through hemodiafiltration. Ren. Fail. 30: 796-800.
Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M 2006 A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin. Rheumatol. 25: 314-319. *
Kwon OS, Park YS, Choi JH, Kim SH, Song MH, Lee HH, Jeon DW, Kim NI 2007 A case of ulcerative colitis relapsed by influenza vaccination. Korean J. Gastroenterol. 49: 327-330.
Labrum R, Bevan S, Sitzer M, Lorenz M, Markus HS 2007 Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke 38: 1179-1184.
Lakoski SG, Li L, Langefeld CD, Liu Y, Howard TD, Brosnihan KB, Xu J, Bowden DW, Herrington DM 2007 The association between innate immunity gene (IRAK1) and C-reactive protein in the Diabetes Heart Study. Exp. Mol. Pathol. 82: 280-283. *
Lamireau T, Cezard JP, Dabadie A, Goulet O, Lachaux A, Turck D, Maurage C, Morali A, Sokal E, Belli D, Stoller J, Cadranel S, Ginies JL, Viola S, Huet F, Languepin J, Lenaerts C, Bury F, Sarles J 2004 Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm. Bowel Dis. 10: 745-750. *
Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S 2006 Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum. 54: 3119-3125. *
Landowski P, Liberek A, Szlagatys-Sidorkiewicz A, Radys W, Brodzicki J, Szarszewski A, Marek A, Luczak G, Kaminska B 2007 Inflammatory bowel disease in children - an analysis of the clinical symptoms and selected biochemical parameters. Med. Wieku. Rozwoj. 11: 401-407.
Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ 2008 Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am. J. Gastroenterol. 103: 162-169. *
Langmead L, Feakins RM, Goldthorpe S, Holt H, Tsironi E, De Silva A, Jewell DP, Rampton DS 2004 Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment. Pharmacol. Ther. 19: 739-747. *
Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses J, Seifert B, Mandrup-Poulsen T, Donath M 2007 Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes. Ugeskr. Laeger. 169: 3868-3871.
Larson-Meyer DE, Newcomer BR, Heilbronn LK, Volaufova J, Smith SR, Alfonso AJ, Lefevre M, Rood JC, Williamson DA, Ravussin E 2008 Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) 16: 1355-1362. *
Lashner BA 2003 Clinical advances in ulcerative colitis. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland.
Lasisi AO, Abdullahi M 2008 The inner ear in patients with nasal allergy. J. Natl. Med. Assoc. 100: 903-905.
Lawson TM, Amos N, Bulgen D, Williams BD 2001 Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 40: 329-335. *
Le Lan C, Ropert M, Laine F, Medevielle M, Jard C, Pouchard M, Le Treut A, Moirand R, Loreal O, Brissot P 2004 Serum ceruloplasmin and ferroxidase activity are not decreased in hepatic failure related to alcoholic cirrhosis: clinical and pathophysiological implications. Alcohol Clin. Exp. Res. 28: 775-779.
Lee DH, Blomhoff R, Jacobs DR Jr 2004 Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic. Res. 38: 535-539.
Lee E, Lee S, Park Y 2008 n-3 Polyunsaturated fatty acids and trans fatty acids in patients with the metabolic syndrome: a case-control study in Korea. Br. J. Nutr. 100: 609-614. *
Lee HS 2005 Diagnosis and predicting severity in acute pancreatitis. Korean J. Gastroenterol. 46: 333-338.
Lee JU, Kim YH, Lee SY, Kim KH, Chung CH, Kim KH, Son HJ, Rhee PL, Kim JJ, Rhee JC 2004 Dose ascites mean more severe Crohn's disease? Korean J. Gastroenterol. 43: 304-309.
Lee SA, Tsai HT, Ou HC, Han CP, Tee YT, Chen YC, Wu MT, Chou MC, Wang PH, Yang SF 2008 Plasma interleukin-1beta, -6, -8 and tumor necrosis factor-alpha as highly informative markers of pelvic inflammatory disease. Clin. Chem. Lab. Med. 46: 997-1003.
Lee SD, Chen LM, Kuo WW, Shu WT, Kuo WH, Huang EJ, Tsai CC, Li PC, Liu JY, Chen TH, Huang CY 2006 Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease. Clin. Chim. Acta 367: 62-68. *
Lee YH, Pratley RE 2005 The evolving role of inflammation in obesity and the metabolic syndrome. Curr. Diab. Rep. 5: 70-75.
Lehrke M, Konrad A, Schachinger V, Tillack C, Seibold F, Stark R, Parhofer KG, Broedl UC 2007 CXCL16 is a surrogate marker of inflammatory bowel disease. Scand. J. Gastroenterol. Oct 12 [Epub ahead of print]. *
Lehrke M, Millington SC, Lefterova M, Cumaranatunge RG, Szapary P, Wilensky R, Rader DJ, Lazar MA, Reilly MP 2007 CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J. Am. Coll. Cardiol. 49: 442-449.
Leiper K, Morris AI, Rhodes JM 2000 Open label trial of oral clarithromycin in active Crohn's disease. Aliment. Pharmacol. Ther. 14: 801-806. *
Lemann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Modigliani R, Bouhnik Y 2005 A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 128: 1812-1818. *
Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, Roberts PF, Woo P, Grattan CE, Hawkins PN 2006 Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch. Dermatol. 142: 1591-1597.
Levalampi T, Honkanen V, Lahdenne P, Nieminen R, Hakala M, Moilanen E 2007 Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand. J. Rheumatol. 36: 189-193.
Levy H, Kalish LA, Cannon CL, Garcia KC, Gerard C, Goldmann D, Pier GB, Weiss ST, Colin AA 2008 Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients. Pediatr. Pulmonol. 43: 463-471.
Levy H, Kalish LA, Huntington I, Weller N, Gerard C, Silverman EK, Celedon JC, Pier GB, Weiss ST 2007 Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatr. Pulmonol. 42: 256-262.
Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY 2008 Clinical study of etanercept for treating ankylosing spondylitis. Nan Fang Yi Ke Da Xue Xue Bao 28: 1349-1351.
Liao HT, Chen HA, Chen CH, Wang HP, Tsai CY, Chang HN, Chou CT 2006 Undifferentiated spondyloarthropathy in Chinese patients. Arch. Med. Res. 37: 384-387.
Liao HT, Lin KC, Chen CH, Liang TH, Lin MW, Tsai CY, Tak Yan Yu D, Chou CT 2007 Human leukocyte antigens in undifferentiated spondyloarthritis. Semin. Arthritis Rheum. 37: 198-201.
Liepa GU, Basu H 2003 C-reactive proteins and chronic disease: what role does nutrition play? Nutr. Clin. Pract. 18: 227-233.
Lindqvist UR, Alenius GM, Husmark T, Theander E, Holmstrom G, Larsson PT 2008 The Swedish Early Psoriatic Arthritis Register - 2-year followup: a comparison with early rheumatoid arthritis. J. Rheumatol. 35: 668-673.
Listrom C, Holt K 2004 Inflammatory bowel disease. Emerg. Med. 36: 24-28.
Lithander FE, Keogh GF, Wang Y, Cooper GJ, Mulvey TB, Chan YK, McArdle BH, Poppitt SD 2008 No evidence of an effect of alterations in dietary fatty acids on fasting adiponectin over 3 weeks. Obesity (Silver Spring) 16: 592-599. *
Liu B, Guo CY, Liu WQ, Wu N, Xing Q 2005 The value of erythrocyte sedimentation rate and C-reactive protein in evaluating disease activity in ankylosing spondylitis. Zhonghua Nei Ke Za Zhi 44: 566-569.
Liu MF, Lin LH, Weng CT, Weng MY 2008 Decreased CD4+CD25+bright T cells in peripheral blood of patients with primary Sjogren's syndrome. Lupus 17: 34-39.
Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, Ollier WE, Martin J, Gonzalez-Gay MA 2007 Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of Northwestern Spain. Semin. Arthritis Rheum. 37: 31-38. *
Lobrano A, Blanchard K, Rock W, Johnson W, Schmieg B, Borman K, Araghizadeh F, Minocha A, Abell TL 2006 Assessing thrombosis risk in patients with idiopathic, diabetic, and postsurgical gastroparesis. Adv. Ther. 23: 750-768.
Loftus EV Jr 2007 Objective measures of disease activity: alternatives to symptom indices. Rev. Gastroenterol. Disord. 7 Suppl. 2: S8-S16.
Lomer MC, Grainger SL, Ede R, Catterall AP, Greenfield SM, Cowan RE, Vicary FR, Jenkins AP, Fidler H, Harvey RS, Ellis R, McNair A, Ainley CC, Thompson RP, Powell JJ 2005 Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn's disease. Eur. J. Gastroenterol. Hepatol. 17: 377-384.
Lopez L, Arai K, Gimenez E, Jimenez M, Pascuzo C, Rodriguez-Bonfante C, Bonfante-Cabarcas R 2006 C-reactive protein and interleukin-6 serum levels increase as Chagas disease progresses towards cardiac failure. Rev. Esp. Cardiol. 59: 50-56.
Lopez-Garcia E, Schulze MB, Manson JE, Meigs JB, Albert CM, Rifai N, Willett WC, Hu FB 2004 Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J. Nutr. 134: 1806-1811. *
Lopez-Olivo MA, Gonzalez-Lopez L, Garcia-Gonzalez A, Villa-Manzano AI, Cota-Sanchez AR, Salazar-Paramo M, Varon-Villalpando E, Cardona-Munoz EG, Gamez-Nava JI 2006 Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis. Scand. J. Rheumatol. 35: 112-116. *
Lotito AP, Campa A, Silva CA, Kiss MH, Mello SB 2007 Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J. Rheumatol. 34: 823-830.
Louis E, El Ghoul Z, Vermeire S, Dall'Ozzo S, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Colombel JF, Watier H 2004 Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. 19: 511-519. *
Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J 2002 A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. J. Gastroenterol. 37: 818-824. *
Louis EJ, Watier HE, Schreiber S, Hampe J, Taillard F, Olson A, Thorne N, Zhang H, Colombel JF 2006 Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet. Genomics 16: 911-914.
Lu S, Zhou W, Zhang Q, Yu XY, Liu DM, Liu XY 2007 Juvenile psoriatic arthritis. Zhongguo Dang Dai Er Ke Za Zhi 9: 339-342.
Lucidi V, Ciabattoni G, Bella S, Barnes PJ, Montuschi P 2008 Exhaled 8-isoprostane and prostaglandin E(2) in patients with stable and unstable cystic fibrosis. Free Radic. Biol. Med. Jun 30 [Epub ahead of print].
Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Dinarello CA, Tilg H 2004 Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin. Exp. Immunol. 138: 323-329. *
Macdonald J, McDonald J 2007 Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 1: CD006097. *
Macdonald J, McDonald J 2006 Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 3: CD006097. *
MacDonald N 2007 Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. J. Support Oncol. 5: 157-162.
Maconi G, Greco S, Duca P, Ardizzone S, Massari A, Cassinotti A, Radice E, Bianchi Porro G 2008 Prevalence and clinical significance of sonographic evidence of mesenteric fat alterations in Crohn's disease. Inflamm. Bowel Dis. Jun 2 [Epub ahead of print].
Madland TM, Apalset EM, Johannessen AE, Brun JG 2005 Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. J. Rheumatol. 32: 1918-1922.
Magee TR, Han G, Cherian B, Khorram O, Ross MG, Desai M 2008 Down-regulation of transcription factor peroxisome proliferator-activated receptor in programmed hepatic lipid dysregulation and inflammation in intrauterine growth-restricted offspring. Am. J. Obstet. Gynecol. 199: 271.e1-e5.
Mahadeva R, Westerbeek RC, Perry DJ, Lovegrove JU, Whitehouse DB, Carroll NR, Ross-Russell RI, Webb AK, Bilton D, Lomas DA 1998 Alpha1-antitrypsin deficiency alleles and the Taq-I G-->A allele in cystic fibrosis lung disease. Eur. Respir. J. 11: 873-879. *
Maharshak N, Arbel Y, Bornstein NM, Gal-Oz A, Gur AY, Shapira I, Rogowski O, Berliner S, Halpern Z, Dotan I 2007 Inflammatory bowel disease is not associated with increased intimal media thickening. Am. J. Gastroenterol. 102: 1050-1055. *
Mahmud N, O'Toole D, O'Hare N, Freyne PJ, Weir DG, Kelleher D 2002 Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment. Pharmacol. Ther. 16: 207-215. *
Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T 2006 Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54: 2817-2829. *
Maire F, Beaugerie L, Cohen M, Deschamps A, Cosnes J, Capeau J, Gendre JP 2001 Factors associated with hyperhomocysteinemia in Crohn's disease. Gastroenterol. Clin. Biol. 25: 745-748.
Majithia V, Harisdangkul V 2005 Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 44: 386-389. *
Maksimowicz-McKinnon K, Magder LS, Petri M 2006 Predictors of carotid atherosclerosis in systemic lupus erythematosus. J. Rheumatol. 33: 2458-2463.
Maksymowych WP, Landewe R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, Poole AR, Wang N, van der Heijde D 2007 Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum. 56: 1846-1853. *
Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis J Jr 2005 Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J. Rheumatol. 32: 1911-1917.
Malarstig A, Eriksson P, Hamsten A, Lindahl B, Wallentin L, Siegbahn A 2008 Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart 94: 724-729.
Manki A, Nishikomori R, Nakata-Hizume M, Kunitomi T, Takei S, Urakami T, Morishima T 2006 Tumor necrosis factor receptor-associated periodic syndrome mimicking systemic juvenile idiopathic arthritis. Allergol. Int. 55: 337-341. *
Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, Latini R 2006 The long pentraxin PTX3 in vascular pathology. Vascul. Pharmacol. 45: 326-330. *
Maor I, Rainis T, Lanir A, Lavy A 2008 Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn's disease: distinction between active and non-active disease. Dig. Dis. Sci. 53: 2208-2214. *
Margalit M, Israeli E, Shibolet O, Zigmond E, Klein A, Hemed N, Donegan JJ, Rabbani E, Goldin, E, Ilan Y 2006 A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel�, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am. J. Gastroenterol. 101: 561-568. *
Mariette X, Ravaud